Cargando…

Metoprolol/sacubitril/valsartan/spironolactone: Lack of efficacy: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602497/ http://dx.doi.org/10.1007/s40278-021-05768-0

Ejemplares similares

Metoprolol: Lack of efficacy in ventricular tachycardia: case report
Publicado: (2020)

Bendroflumethiazide/sacubitril/valsartan: Hyperkalaemia and hyponatraemia: 8 case reports
Publicado: (2021)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
por: Bonatto, Marcely Gimenes, et al.
Publicado: (2020)

Use of sacubitril/valsartan in acute decompensated heart failure: a case report
por: Bell, Taison D., et al.
Publicado: (2017)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
por: Rawla, Prashanth, et al.
Publicado: (2019)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)

Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report
por: Bell, Elisabeth, et al.
Publicado: (2022)

A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy
por: De Vecchis, Renato, et al.
Publicado: (2020)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report
por: Lupi, Alessandro, et al.
Publicado: (2021)

Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report
por: Li, Jia-Min, et al.
Publicado: (2019)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril/valsartan: a case report
por: Siew, Kelvin Shenq Woei, et al.
Publicado: (2022)

Effect of add-on sacubitril/valsartan on the left ventricular hypertrophy of a patient with hypertension
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report
por: Corrado, Egle, et al.
Publicado: (2020)

Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case Report
por: Barry, Arden R.
Publicado: (2020)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

Resolution of Hypoglycemia Following Cessation of Sacubitril–Valsartan Combination Therapy in a Nondiabetic Patient
por: Morgan, Georgia, et al.
Publicado: (2022)

Sacubitril/Valsartan Shows Improvement of the Cardio-Ankle Vascular Index in a Hypertensive Patient
por: Shimizu, Kazuhiro, et al.
Publicado: (2023)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
por: Abdin, Amr, et al.
Publicado: (2022)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy: The first case report
por: Spoto, Silvia, et al.
Publicado: (2019)

Sacubitril/valsartan-induced liver injury: A case report and literature review
por: Zhang, Ting, et al.
Publicado: (2023)

Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman
por: Faber, Eve S., et al.
Publicado: (2016)

Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review
por: Mohyeldin, Moiud, et al.
Publicado: (2021)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6u2g54pg03m17c6j4vvcrdeq4q